

S 2244

Prescription Drug Price Parity for Americans Act

Congress: 107 (2001–2003, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Apr 24, 2002

Current Status: Sponsor introductory remarks on measure. (CR S3794, S3795)

Latest Action: Sponsor introductory remarks on measure. (CR S3794, S3795) (May 2, 2002)

Official Text: <https://www.congress.gov/bill/107th-congress/senate-bill/2244>

Sponsor

Name: Sen. Dorgan, Byron L. [D-ND]

Party: Democratic • State: ND • Chamber: Senate

Cosponsors (11 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Collins, Susan M. [R-ME]	R · ME		Apr 24, 2002
Sen. Dayton, Mark [D-MN]	D · MN		Apr 24, 2002
Sen. Jeffords, James M. [I-VT]	I · VT		Apr 24, 2002
Sen. Levin, Carl [D-MI]	D · MI		Apr 24, 2002
Sen. Snowe, Olympia J. [R-ME]	R · ME		Apr 24, 2002
Sen. Stabenow, Debbie [D-MI]	D · MI		Apr 24, 2002
Sen. Wellstone, Paul D. [D-MN]	D · MN		Apr 24, 2002
Sen. Johnson, Tim [D-SD]	D · SD		Apr 25, 2002
Sen. Miller, Zell [D-GA]	D · GA		May 7, 2002
Sen. Durbin, Richard J. [D-IL]	D · IL		May 13, 2002
Sen. Feingold, Russell D. [D-WI]	D · WI		Jul 8, 2002

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Apr 24, 2002

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
107 HR 4614	Related bill	May 6, 2002: Referred to the Subcommittee on Health.

Prescription Drug Price Parity for Americans Act - Amends provisions of the Federal Food, Drug, and Cosmetic Act set forth in the Medicine Equity and Drug Safety Act of 2000 to: (1) direct the Secretary of Health and Human Services to promulgate regulations permitting pharmacists and wholesalers to import Food and Drug Administration (FDA)-approved prescription drugs from Canada (currently, from Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa, the countries in the European Union and the European Free Trade Association, or other countries designated by the Secretary); and (2) exclude an infused or intravenously injected drug or a drug that is inhaled during surgery.

Prohibits discrimination in the sale of prescription drugs by manufacturers to pharmacists or wholesalers, requiring: (1) terms as favorable as those provided to foreign purchasers; and (2) full access to drugs permitted to be imported.

Continues the requirement that exported donated prescription drugs may only be reimported by the manufacturer.

Permits the Secretary to waive the prohibition against importing a prescription drug or device on a case-by-case basis, particularly those from Canada that are FDA-approved and for limited personal use.

Requires a study and report by the: (1) Institute of Medicine of the National Academy of Sciences on the regulatory compliance of importers of drugs; and (2) Comptroller General on how drug prices were affected.

Actions Timeline

- **May 2, 2002:** Sponsor introductory remarks on measure. (CR S3794, S3795)
- **Apr 24, 2002:** Introduced in Senate
- **Apr 24, 2002:** Sponsor introductory remarks on measure. (CR S3316)
- **Apr 24, 2002:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S3316-3318)